Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.

ABSTRACT:

Introduction

Carbonic anhydrase IX (CAIX) is a hypoxia regulated metalloenzyme integral to maintaining cellular pH. Increased CAIX expression is associated with poor prognosis in breast cancer. To explore CAIX as a biomarker for breast cancer therapies, we measured plasma CAIX levels in healthy control subjects and in breast cancer patients.

Methods

In control subjects we evaluated plasma CAIX stability via commercially available ELISA. We then similarly quantified plasma CAIX levels in (1) locally advanced breast cancer (LABC) patients treated with neoadjuvant paclitaxel + sunitinib (T + S) followed by doxorubicin and cyclophosphamide (AC); (2) metastatic breast cancer (MBC) patients treated with systemic chemotherapy.

Results

Plasma CAIX levels were stable at room t

SUBMITTER: Brown-Glaberman U 

PROVIDER: S-EPMC4749816 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature